Journal ArticleOPEN ACCESS

Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020

  • Thompson W
  • Symum H
  • et al.
MMWR. Morbidity and Mortality Weekly Report (2022) 71(32) 1011-1017
DOI: 10.15585/mmwr.mm7132e1
113Citations
Citations of this article
45Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Over 2 million adults in the United States have hepatitis C virus (HCV) infection, and it contributes to approximately 14,000 deaths a year. Eight to 12 weeks of highly effective direct-acting antiviral (DAA) treatment, which can cure ≥95% of cases, is recommended for persons with hepatitis C.

Cite

CITATION STYLE

APA

Thompson, W. W., Symum, H., Sandul, A., Gupta, N., Patel, P., … Wester, C. (2022). Vital Signs: Hepatitis C Treatment Among Insured Adults — United States, 2019–2020. MMWR. Morbidity and Mortality Weekly Report, 71(32), 1011–1017. https://doi.org/10.15585/mmwr.mm7132e1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free